Third Harmonic Bio, Inc.
NASDAQ: THRD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Natalie C. Holles
- Employees
- 31
- Headquarters
- Cambridge, United States
- IPO year
- 2022
- Market cap
- $242.8M
- Website
- https://www.thirdharmonicbio.com
Loading THRD…
Loading profile data…Frequently asked questions about THRD
What does Third Harmonic Bio, Inc. (THRD) do?
Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailme...
Where does THRD trade?
Third Harmonic Bio, Inc. (THRD) trades on the NASDAQ Global Market.
What sector is THRD in?
Third Harmonic Bio, Inc. (THRD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Third Harmonic Bio, Inc.?
Natalie C. Holles is the chief executive officer of Third Harmonic Bio, Inc. (THRD).
Where is Third Harmonic Bio, Inc. headquartered?
Third Harmonic Bio, Inc. is headquartered in United States.
Does THRD pay a dividend?
Third Harmonic Bio, Inc. (THRD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did THRD go public?
Third Harmonic Bio, Inc. (THRD) completed its initial public offering in 2022.